CFBK
CF Bankshares Inc.
CFBK offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
MS
Morgan Stanley
MS has a slight edge over CFBK overall, supported by stronger valuation and stronger modeled upside.
CFBK Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| N/A | |
| N/A |
CFBK's profitability is currently strong, and its revenue is stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like CFBK.
MS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
MS's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like MS.
CFBK PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 4.8x | $16.50 | -53% |
| Fair | 7.7x | $26.58 | -25% |
| Forward | 8.7x | $35.32 | — |
| Current | 10x | $35.32 | — |
| Expensive | 11x | $37.27 | +5.5% |
Historical ranges are pointers, not guarantees.
CFBK's PE is in its expensive range at 10x. If earnings grow as analysts expect, today's price would be 8.7x next year's earnings.
MS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $134 | -29% |
| Fair | 14x | $178 | -5.7% |
| Forward | 14x | $189 | — |
| Current | 15x | $189 | — |
| Expensive | 18x | $223 | +18% |
Historical ranges are pointers, not guarantees.
MS has the edge over CFBK in the historical PE scenario, which offers more potential upside but is not a forecast.
CFBK Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for CFBK, with profitability improving.
MS Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for MS, with profitability improving.
CFBK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.08 | +18% |
| Q3 2026 | $3.46 | +39% |
| Q2 2026 | $2.91 | +4.7% |
| Q1 2026 | $2.78 | +22% |
| Q4 2025 | $2.69 | +31% |
| Q3 2025 | $2.49 | +21% |
| Q2 2025 | $2.78 | +38% |
| Q1 2025 | $2.27 | -6.2% |
| Q4 2024 | $2.06 | -22% |
CFBK's earnings per share have fallen from their peak: $3.46 over the past year, against $5.13 in early 2021.
MS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.39 | +6.3% |
| Q3 2026 | $12.60 | +29% |
| Q2 2026 | $12.37 | +40% |
| Q1 2026 | $11.04 | +29% |
| Q4 2025 | $10.21 | +28% |
| Q3 2025 | $9.76 | +48% |
| Q2 2025 | $8.84 | +45% |
| Q1 2025 | $8.53 | +55% |
| Q4 2024 | $7.95 | +53% |
MS has the edge over CFBK on earnings, with more consistent year-over-year improvement.
CFBK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $16.7M | +7.7% |
| Q2 2026 | $16.5M | +6.2% |
| Q1 2026 | $14.8M | +4.9% |
| Q4 2025 | $15.7M | +13% |
| Q3 2025 | $15.5M | +19% |
| Q2 2025 | $15.6M | +24% |
| Q1 2025 | $14.1M | +16% |
| Q4 2024 | $14M | +9.3% |
CFBK's revenue has grown year over year for 10 quarters in a row: $17M last quarter, up 7.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 44% | +27 points |
| Q2 2026 | 44% | +2.8 points |
| Q1 2026 | 40% | +0.3 points |
| Q4 2025 | 43% | +6.5 points |
| Q3 2025 | 17% | -23 points |
| Q2 2025 | 41% | +26 points |
| Q1 2025 | 40% | +8.6 points |
| Q4 2024 | 37% | -3.5 points |
CFBK has the edge over MS on profitability, with a higher operating margin.
MS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.3B | +12% |
| Q2 2026 | $21.3B | +27% |
| Q1 2026 | $20.6B | +16% |
| Q4 2025 | $17.9B | +10% |
| Q3 2025 | $18.2B | +18% |
| Q2 2025 | $16.8B | +12% |
| Q1 2025 | $17.7B | +17% |
| Q4 2024 | $16.2B | +26% |
MS has the edge over CFBK on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 32% | -1.2 points |
| Q2 2026 | 34% | +6.9 points |
| Q1 2026 | 34% | +2.8 points |
| Q4 2025 | 32% | +2 points |
| Q3 2025 | 33% | +5.6 points |
| Q2 2025 | 28% | +0.4 points |
| Q1 2025 | 31% | +2.2 points |
| Q4 2024 | 30% | +14 points |
MS's operating margin was 32% last quarter, down 1.2 points from the same quarter a year ago.
CFBK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.4M | +61% |
| Q2 2026 | $5M | -36% |
| Q1 2026 | $4.6M | +115% |
| Q4 2025 | $3M | -76% |
| Q3 2025 | $5.2M | +$6.5M |
| Q2 2025 | $7.8M | +97% |
| Q1 2025 | $2.2M | +$3.3M |
| Q4 2024 | $12.4M | +56% |
CFBK has the edge over MS on cash generation, producing positive trailing cash flow while its opponent burns cash.
MS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$46B | -$42.7B |
| Q2 2026 | -$2.7B | -123% |
| Q1 2026 | -$7.1B | +$16.9B |
| Q4 2025 | -$2.4B | -120% |
| Q3 2025 | -$3.3B | +$14B |
| Q2 2025 | $11.8B | +368% |
| Q1 2025 | -$24B | -650% |
| Q4 2024 | $11.8B | +$29.6B |
MS's free cash flow was −$58.3B over the past year, against −$3.7B the year before. Free cash flow isn't a meaningful measure for financial services companies like MS.
CFBK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.8% | +112K shares |
| 1 year | +2% | +129K shares |
| 3 years | +0.3% | +18.9K shares |
| 5 years | -2.7% | -182K shares |
| Available history | +40% | +1.8M shares |
CFBK has 6M diluted shares, up 2% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $150,000 |
| Q4 2025 | $440,000 |
| Q3 2025 | $76,000 |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | $44,000 |
| Q1 2024 | $179,000 |
| Q4 2022 | — |
MS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -3M shares |
| 1 year | -1.5% | -24M shares |
| 3 years | -4.7% | -77M shares |
| 5 years | -14% | -246M shares |
| Available history | -4.5% | -74M shares |
MS has the edge over CFBK on shareholder dilution, with a more favorable share count trend.
CFBK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -8.4x | Net Cash |
| Q2 2026 | -10.3x | Net Cash |
| Q1 2026 | -11.3x | Net Cash |
| Q4 2025 | -11.1x | Net Cash |
| Q3 2025 | -12.7x | Net Cash |
| Q2 2025 | -11.4x | Net Cash |
| Q1 2025 | -12.3x | Net Cash |
| Q4 2024 | -13.3x | Net Cash |
CFBK has the edge over MS on leverage, with a lower net debt burden relative to earnings.
MS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 7.8x | High |
| Q2 2026 | 7.3x | High |
| Q1 2026 | 8.2x | High |
| Q4 2025 | 8.6x | High |
| Q3 2025 | 8.4x | High |
| Q2 2025 | 8.7x | High |
| Q1 2025 | 8.7x | High |
| Q4 2024 | 7.9x | High |
MS's net debt is about 7.8 years of its operating earnings (EBITDA), down from 8.4 years a year ago. Net leverage isn't a meaningful measure for financial services companies like MS.
CFBK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 62.7 | Neutral |
| Stochastic | 31.5 | Neutral |
CFBK's weekly RSI is 63 (neutral) and its Stochastic is 31 (neutral).
MS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.0 | Neutral |
| Stochastic | 18.7 | Oversold |
MS's weekly RSI is 45 (neutral) and its Stochastic is 19 (oversold).
CFBK PE vs Financial Services Sector
| Metric | CFBK | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 13x | 22% below |
| PE % | 75 | 63 | 12 pts above |
CFBK has the edge over MS on valuation relative to its sector.
MS PE vs Financial Services Sector
| Metric | MS | Sector median | Relative |
|---|---|---|---|
| PE | 15x | 13x | 15% above |
| PE % | 59 | 63 | 4 pts below |
MS is trading at 15x earnings, a 15% premium to the Financial Services sector's median of 13x.
CFBK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $34.4 | 2.7% above |
| 20 week MA | $34.4 | 2.7% above |
| 50 week MA | $30.9 | 14% above |
| 100 week MA | $27.2 | 30% above |
| 200 week MA | $23.5 | 51% above |
CFBK has the edge over MS on trend strength, trading above more of its moving averages.
MS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $186.5 | 1.5% above |
| 20 week MA | $203.3 | 6.9% below |
| 50 week MA | $191.9 | 1.4% below |
| 100 week MA | $164.9 | 15% above |
| 200 week MA | $129.3 | 46% above |
MS's trend is mixed: it's above three of its five weekly moving averages, and 46% above its 200-week average.
CFBK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $14.1 | $18.0 | +28% |
| 2021 | $18.0 | $21.5 | +19% |
| 2022 | $21.5 | $21.4 | -0.4% |
| 2023 | $21.4 | $19.5 | -8.8% |
| 2024 | $19.5 | $23.9 | +23% |
| 2025 | $23.9 | $25.9 | +8.2% |
| 2026 YTD | $25.9 | $35.3 | +36% |
CFBK has the edge over MS on returns for 2026, with the stronger performance.
MS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $51.1 | $68.1 | +33% |
| 2021 | $68.1 | $99.3 | +46% |
| 2022 | $99.3 | $86.1 | -13% |
| 2023 | $86.1 | $93.3 | +8.3% |
| 2024 | $93.3 | $126.8 | +36% |
| 2025 | $126.8 | $181.9 | +43% |
| 2026 YTD | $181.9 | $189.2 | +4% |
MS has finished higher in five of the last six years. It's up 4% so far in 2026.